343 related articles for article (PubMed ID: 32161599)
1. Immunotherapies in Huntington's disease and α-Synucleinopathies.
Fatoba O; Ohtake Y; Itokazu T; Yamashita T
Front Immunol; 2020; 11():337. PubMed ID: 32161599
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy and immunotherapy as promising strategies to combat Huntington's disease-associated neurodegeneration: emphasis on recent updates and future perspectives.
Jamwal S; Elsworth JD; Rahi V; Kumar P
Expert Rev Neurother; 2020 Nov; 20(11):1123-1141. PubMed ID: 32720531
[TBL] [Abstract][Full Text] [Related]
3. Are immunotherapies for Huntington's disease a realistic option?
Denis HL; Lauruol F; Cicchetti F
Mol Psychiatry; 2019 Mar; 24(3):364-377. PubMed ID: 29487401
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?
Björkqvist M
J Neurochem; 2016 Jun; 137(5):670-2. PubMed ID: 27059524
[TBL] [Abstract][Full Text] [Related]
5. Emerging antibody-based therapies for Huntington's disease: current status and perspectives for future development.
Jurcau A; Simion A; Jurcau MC
Expert Rev Neurother; 2024 Mar; 24(3):299-312. PubMed ID: 38324338
[TBL] [Abstract][Full Text] [Related]
6. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
Wright DJ; Renoir T; Gray LJ; Hannan AJ
Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammation in Huntington's Disease: New Insights with
Lois C; González I; Izquierdo-García D; Zürcher NR; Wilkens P; Loggia ML; Hooker JM; Rosas HD
ACS Chem Neurosci; 2018 Nov; 9(11):2563-2571. PubMed ID: 29719953
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in Huntington's disease.
Bashir H
Expert Rev Neurother; 2019 Oct; 19(10):983-995. PubMed ID: 31181964
[No Abstract] [Full Text] [Related]
9. Inflammation and Huntington's disease - a neglected therapeutic target?
Field SE; Curle AJ; Barker RA
Expert Opin Investig Drugs; 2024 May; 33(5):451-467. PubMed ID: 38758356
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders.
Kimura Y; Lee WC; Littleton JT
Mini Rev Med Chem; 2007 Jan; 7(1):99-106. PubMed ID: 17266642
[TBL] [Abstract][Full Text] [Related]
12. Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies.
Rocha NP; Ribeiro FM; Furr-Stimming E; Teixeira AL
Mediators Inflamm; 2016; 2016():8653132. PubMed ID: 27578922
[TBL] [Abstract][Full Text] [Related]
13. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Clark LF; Kodadek T
ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
[TBL] [Abstract][Full Text] [Related]
14. Distinct neuroinflammatory profile in post-mortem human Huntington's disease.
Silvestroni A; Faull RL; Strand AD; Möller T
Neuroreport; 2009 Aug; 20(12):1098-103. PubMed ID: 19590393
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
16. Antiglutamate therapies in Huntington's disease.
Kieburtz K
J Neural Transm Suppl; 1999; 55():97-102. PubMed ID: 10335496
[TBL] [Abstract][Full Text] [Related]
17. Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis.
Andre R; Carty L; Tabrizi SJ
Curr Opin Pharmacol; 2016 Feb; 26():33-8. PubMed ID: 26461267
[TBL] [Abstract][Full Text] [Related]
18. Essential fatty acids in Huntington's disease.
Das UN; Vaddadi KS
Nutrition; 2004 Oct; 20(10):942-7. PubMed ID: 15474886
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood inflammatory cytokines in prodromal and overt α-synucleinopathies: a review of current evidence.
Jun JS; Kim R
Encephalitis; 2023 Jul; 3(3):81-86. PubMed ID: 37500099
[TBL] [Abstract][Full Text] [Related]
20. The P42 peptide and Peptide-based therapies for Huntington's disease.
Marelli C; Maschat F
Orphanet J Rare Dis; 2016 Mar; 11():24. PubMed ID: 26984770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
